pubmed-article:9822711 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0035143 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0011777 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0012472 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0387583 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0040649 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0030685 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0680255 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0391871 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C1283071 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C1963578 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C1709305 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0441712 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C1517945 | lld:lifeskim |
pubmed-article:9822711 | lifeskim:mentions | umls-concept:C0071504 | lld:lifeskim |
pubmed-article:9822711 | pubmed:issue | 48 | lld:pubmed |
pubmed-article:9822711 | pubmed:dateCreated | 1998-12-23 | lld:pubmed |
pubmed-article:9822711 | pubmed:abstractText | The two cyclooxygenase (COX) isoforms convert arachidonic acid to precursor prostaglandins (PGs). Up-regulation of COX-2 is responsible for increased PG production in inflammation and is antagonized by corticosteriods such as dexamethasone. In human pulmonary A549 cells, interleukin-1beta (IL-1beta) increases prostaglandin E2 (PGE2) synthesis via dexamethasone-sensitive induction of COX-2. Nuclear run-off assays showed that COX-2 transcription rate was repressed 25-40% by dexamethasone, while PGE2 release, COX activity, and COX-2 protein were totally repressed. At the mRNA level, complete repression of COX-2 was only observed at later (6 h) time points. Preinduced COX-2 mRNA was also potently repressed by dexamethasone, yet suppression of transcription by actinomycin D showed little effect. This dexamethasone-dependent repression involved a reduced COX-2 mRNA half-life, was blocked by actinomycin D or cycloheximide, and was antagonized by the steroid antagonist RU38486. Repression of IL-1beta-induced PGE2 release, COX activity, and COX-2 protein by actinomycin D was only effective within the first hour following IL-1beta treatment, while dexamethasone was effective when added up to 10 h later, suggesting a functional role for post-transcriptional mechanisms of repression. Following dexamethasone treatment, shortening of the average length of COX-2 mRNA poly(A) tails was observed. Finally, ligation of the COX-2 3'-UTR to a heterologous reporter failed to confer dexamethasone sensitivity. In conclusion, these data indicate a major role for post-transcriptional mechanisms in the dexamethasone-dependent repression of COX-2 that require de novo glucocorticoid receptor-dependent transcription and translation. This mechanism involves shortening of the COX-2 poly(A) tail and requires determinants other than just the 3'-UTR for specificity. | lld:pubmed |
pubmed-article:9822711 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:language | eng | lld:pubmed |
pubmed-article:9822711 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9822711 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:9822711 | pubmed:month | Nov | lld:pubmed |
pubmed-article:9822711 | pubmed:issn | 0021-9258 | lld:pubmed |
pubmed-article:9822711 | pubmed:author | pubmed-author:SeyboldJJ | lld:pubmed |
pubmed-article:9822711 | pubmed:author | pubmed-author:BarneyP LPL | lld:pubmed |
pubmed-article:9822711 | pubmed:author | pubmed-author:BergmannMM | lld:pubmed |
pubmed-article:9822711 | pubmed:author | pubmed-author:NewtonRR | lld:pubmed |
pubmed-article:9822711 | pubmed:author | pubmed-author:KuitertL MLM | lld:pubmed |
pubmed-article:9822711 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:9822711 | pubmed:day | 27 | lld:pubmed |
pubmed-article:9822711 | pubmed:volume | 273 | lld:pubmed |
pubmed-article:9822711 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:9822711 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:9822711 | pubmed:pagination | 32312-21 | lld:pubmed |
pubmed-article:9822711 | pubmed:dateRevised | 2009-9-29 | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:meshHeading | pubmed-meshheading:9822711-... | lld:pubmed |
pubmed-article:9822711 | pubmed:year | 1998 | lld:pubmed |
pubmed-article:9822711 | pubmed:articleTitle | Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. | lld:pubmed |
pubmed-article:9822711 | pubmed:affiliation | Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, United Kingdom. robert.newton@ic.ac.uk | lld:pubmed |
pubmed-article:9822711 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:9822711 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9822711 | lld:pubmed |